These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 28204995)

  • 1. Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria.
    Dranitsaris G; Shane LG; Galanaud JP; Stemer G; Debourdeau P; Woodruff S
    Support Care Cancer; 2017 Jul; 25(7):2093-2102. PubMed ID: 28204995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic Analysis Comparing Dalteparin to Vitamin K Antagonists to Prevent Recurrent Venous Thromboembolism in Patients With Cancer Having Renal Impairment.
    Dranitsaris G; Shane L; Burgers L; Woodruff S
    Clin Appl Thromb Hemost; 2016 Oct; 22(7):617-26. PubMed ID: 27436663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis.
    Dranitsaris G; Shane LG; Crowther M; Feugere G; Woodruff S
    Clinicoecon Outcomes Res; 2017; 9():65-73. PubMed ID: 28138260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences.
    Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
    BMC Health Serv Res; 2017 Jan; 17(1):74. PubMed ID: 28114939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysis.
    Dranitsaris G; Vincent M; Crowther M
    Pharmacoeconomics; 2006; 24(6):593-607. PubMed ID: 16761906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment.
    Woodruff S; Feugère G; Abreu P; Heissler J; Ruiz MT; Jen F
    J Thromb Thrombolysis; 2016 Nov; 42(4):494-504. PubMed ID: 27344439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery.
    Dranitsaris G; Stumpo C; Smith R; Bartle W
    Am J Cardiovasc Drugs; 2009; 9(1):45-58. PubMed ID: 19178131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-molecular-weight heparins for the prevention of recurrent venous thromboembolism in patients with cancer: A systematic literature review of efficacy and cost-effectiveness.
    Dranitsaris G; Shane LG; Woodruff S
    J Oncol Pharm Pract; 2019 Jan; 25(1):68-75. PubMed ID: 28857713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.
    Fowler RA; Mittmann N; Geerts W; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
    JAMA; 2014 Nov; 312(20):2135-45. PubMed ID: 25362228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial.
    Fowler RA; Mittmann N; Geerts WH; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
    Trials; 2014 Dec; 15():502. PubMed ID: 25528663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
    Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
    Clin Ther; 2016 Mar; 38(3):478-93.e1-16. PubMed ID: 26922297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of dalteparin for preventing venous thromboembolism in abdominal surgery.
    Heerey A; Suri S
    Pharmacoeconomics; 2005; 23(9):927-44. PubMed ID: 16153135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism.
    de Jong LA; van der Velden AWG; Hulst MV; Postma MJ
    BMJ Open; 2020 Nov; 10(11):e039057. PubMed ID: 33444193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of venous thromboembolism in patients with cancer: role of dalteparin.
    Linkins LA
    Vasc Health Risk Manag; 2008; 4(2):279-87. PubMed ID: 18561503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LMWH in cancer patients with renal impairment - better than warfarin?
    Bauersachs RM
    Thromb Res; 2016 Apr; 140 Suppl 1():S160-4. PubMed ID: 27067971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of apixaban compared to low-molecularweight heparins and vitamin k antagonists for treatment and secondary prevention of venous thromboembolism.
    Elías I; Oyagüez I; Alvarez-Sala LA; García-Bragado F; Navarro A; González P; De Andrés-Nogales F; Soto J
    Farm Hosp; 2016 May; 40(3):187-208. PubMed ID: 27145388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-molecular weight heparin versus vitamin K antagonists for the treatment of cancer-associated thrombosis: A cost-effectiveness analysis.
    Connell NT; Abel GA; Connors JM
    Thromb Res; 2017 Feb; 150():53-58. PubMed ID: 28039844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study.
    Woodruff S; Lee AYY; Carrier M; Feugère G; Abreu P; Heissler J
    J Thromb Thrombolysis; 2019 May; 47(4):495-504. PubMed ID: 30859370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands.
    Stevanović J; de Jong LA; Kappelhoff BS; Dvortsin EP; Voorhaar M; Postma MJ
    PLoS One; 2016; 11(10):e0163550. PubMed ID: 27776137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
    McBane Ii R; Loprinzi CL; Ashrani A; Perez-Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Le-Rademacher JG; Wysokinski WE
    Thromb Haemost; 2017 Oct; 117(10):1952-1961. PubMed ID: 28837207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.